Neuland profit surges as operating margin reaches 39.59%
Revenue growth outpaced expense growth by a wide margin, while the tax-rate decline also supported the 664.72% year-on-year rise in net profit.
Filed 12 May 2026, 19:24 IST · after market close · Neuland Laboratories Ltd (NEULANDLAB)
Key takeaways
- Consolidated revenue rose 136.40% year on year as operating margin expanded 24.04 percentage points to 39.59%.
- Consolidated net profit increased 664.72% year on year, helped by a 3.22 percentage-point reduction in the tax rate to 26.03%.
- The stock fell 2.98% on the first trading day after results, a smaller move than its 6.85% median absolute reaction after the past eight results.
Price around the results
Commercial products lift Q4 revenue
Consolidated revenue rose 136.40% year on year and 76.54% sequentially, while expenses increased 69.11% and 29.33%, respectively. That operating leverage drove a 501.78% year-on-year rise in operating profit and a 298.46% sequential increase. Management said the quarter marked a strong end to FY26 and pointed to a steady movement of molecules from clinical stages into commercialisation, increasing commercial-product revenue.
Margin rebound was driven by cost discipline
Operating margin expanded 24.04 percentage points year on year and 22.05 percentage points sequentially because revenue grew faster than expenses. The 39.59% margin was a sharp recovery from 17.54% in Q3FY26, after the margin had fallen from 30.25% in Q2FY26. Other income contributed 4.33% of pre-tax profit, so it was not a major driver of reported earnings quality; however, the year-on-year tax-rate decline of 3.22 percentage points also supported net profit.
Neuland remained above the reported healthcare peer median
Neuland's operating margin was 16.21 percentage points above the 23.38% median for the 48 healthcare peers that had reported the same quarter. The quarterly trend shows a recovery from 11.78% in Q1FY26 and 17.54% in Q3FY26 to 39.59% in Q4FY26, rather than a continuing decline. Management said short- to medium-term visibility is anchored by commercial and near-commercial molecules, while investments in peptide manufacturing and a new R&D centre are proceeding according to plan.
Initial market reaction was mild versus Neuland's history
The stock initially opened 7.66% higher but ended the first trading day 2.98% lower, and remained down 2.23% after five sessions. This was less severe than the stock's typical post-results move: six of its past eight reactions were negative and the median absolute move was 6.85%. Trading volume on the first day was 7.79 times normal, while the five-day relative return versus the benchmark was -3.42%.
Q4FY26 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q4FY26 | Q3FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹776 cr | ₹440 cr | +76.54% | +136.40% |
| Other income | ₹12 cr | ₹8 cr | +54.78% | +67.02% |
| Expenses | ₹469 cr | ₹363 cr | +29.33% | +69.11% |
| Operating profit | ₹307 cr | ₹77 cr | +298.46% | +501.78% |
| Operating margin (%) | 39.59% | 17.54% | — | — |
| Interest | ₹7 cr | ₹7 cr | +6.19% | +206.81% |
| Depreciation | ₹25 cr | ₹24 cr | +4.89% | +48.55% |
| Profit before tax | ₹287 cr | ₹54 cr | +427.70% | +631.53% |
| Tax | ₹75 cr | ₹14 cr | +438.27% | +551.17% |
| Net profit | ₹213 cr | ₹41 cr | +424.21% | +664.72% |
| EPS (₹) | ₹165.76 | ₹31.62 | +424.23% | +664.93% |
Operating margin of 39.59% compares with a Healthcare sector median of 23.38% across 48 peers that have reported Q4FY26.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | -2.98% | -3.12% |
| Next session | -1.90% | — |
| 5 sessions | -2.23% | -3.42% |
| 15 sessions | -0.84% | — |
| 30 sessions | +5.63% | — |
Volume on the results session was 7.79× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Management says FY26 ended on a strong note in line with its original expectations.
- The number of active CMS projects increased to 98 in Q4 FY26 from 97 in Q4 FY25.
- The company reported a steady trend of molecules transitioning from clinical phases to commercialisation, increasing commercial-product revenue.
Guidance & outlook
- Management sees good short- to medium-term business visibility anchored by commercial and near-commercial molecules.
- Management says its growth foundation is being laid beyond the short- to medium-term horizon.
Expansion
- Investments in peptide manufacturing and a new R&D centre are proceeding according to plan.
New initiatives
- The company is focusing on execution discipline, customer satisfaction and protecting business fundamentals during its growth phase.
- The company is aligning its business development strategy with its investments to bring in projects supporting high-quality, sustainable growth.
- The company plans to digitise more than 90% of business processes across key functions by 2030.
Problems & risks
- Expected price declines from higher peptide volumes are identified as a market challenge.
What to watch
- Whether consolidated operating margin holds above 39.59% after the Q4FY26 rebound.
- Whether the number of active CMS projects moves from 98 in Q4FY26.
- Whether the tax rate stays near 26.03% without adding further support to net profit growth.